ARCHIVES

Bevacizumab And Irinotecan May Increase Survival Of GBM

This article is from The Cancer Letter archive.

Vol. 30 No. 10 | October 26, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Seen Shifting Away From Comprehensive Center Emphasis Toward Encouraging Clinical Excellence

April 30, 1976

In Brief: NCI Scientist Accused Of Taking ‘Payoffs’ Forom Drug Firms; GM-CS Wins FDA Approval

March 15, 1991

Anil Potti Resigns From Duke University

November 19, 2010

Improvements Still Needed To Reduce Chemo Errors

November 25, 2005

8 Centers Awarded Comprehensive Designation

February 15, 1991

FDA Approves Erbitux for Head & Neck Cancer.

March 3, 2006